squamous cell carcinoma-related antigen

Subscribe to Selected New Research on squamous cell carcinoma-related antigen

515 relevant articles (20 outcomes, 77 trials/studies) found for this Bio-Agent

Description: useful marker for detecting, staging & for monitoring response to therapy in patients with squamous cell carcinoma of the lung; subfraction of tumor antigen TA-4; has been sequenced; GenBank AB005548

Also Known As:

SCC antigen; SCC-Ag; SCCA1 protein, human; SERPINB3 protein, human; SERPINB4 protein, human; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3, human; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 4, human; squamous cell carcinoma antigen; squamous cell carcinoma antigen 1; squamous cell carcinoma antigen 2; squamous cell carcinoma antigen 2, human

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 931

Antigens: 95584

Neoplasm Antigens: 1577

squamous cell carcinoma-related antigen: 515

Amino Acids, Peptides, and Proteins

Proteins: 58433

Serpins: 132

squamous cell carcinoma-related antigen: 515

Experts

1.	Nawata, Shugo: 5 articles (01/2008 - 02/2004)
2.	Sugino, Norihiro: 5 articles (01/2008 - 02/2004)
3.	Murakami, Akihiro: 5 articles (01/2008 - 02/2004)
4.	Takeda, Osamu: 5 articles (01/2008 - 02/2004)
5.	Nakagawa, Tatsushi: 4 articles (01/2008 - 11/2005)
6.	Kato, Hiroshi: 4 articles (11/2006 - 02/2004)
7.	Sueoka, Kotaro: 3 articles (01/2008 - 02/2004)
8.	Yasumatsu, Ryuji: 3 articles (01/2006 - 01/2002)
9.	Nakashima, Torahiko: 3 articles (01/2006 - 01/2002)
10.	Kuratomi, Yuichiro: 3 articles (01/2006 - 01/2002)

Related Diseases

1.	Neoplasms (Cancer) 04/01/1988 - "The present study indicates that SCC antigen determination is not useful for the early diagnosis of cervical cancer, but it is a potential means for monitoring the efficacy of individual anticancer therapy of SCC of the uterine cervix and for detecting recurrent disease." 06/01/2005 - "Multivariate Cox regression models considering tumor stage, lymph node involvement, patients' age, and SCC-Ag serum levels as covariates showed that lymph node involvement (P = 0.04 and P = 0.01) and tumor stage (P = 0.006 and P = 0.009), but not SCC-Ag serum levels (P = 0.8 and P = 0.6), and patients' age (P = 0.08 and P = 0.22) are prognostic factors for disease-free and overall survival, respectively. " 10/01/2001 - "As long as treatment possibilities for recurrent cervical cancer patients are not improved, serum SCC-ag analysis should not be carried out in routine follow-up." 12/01/1996 - "In addition, we suggest that serum SCC antigen monitoring may be helpful in early detection of cancer recurrence." 11/01/1994 - "Serum squamous cell carcinoma antigen assays and clinical tumor size estimated by colposcopic examination are helpful in identifying patients who require postoperative adjunctive therapy." Order ALL the reference details at left...
2.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/01/1989 - "This manuscript reports the efficacy of using circulating squamous cell carcinoma antigen in evaluating patients with squamous cell carcinoma of the head and neck. " 09/01/2007 - "The aim of the present study was to evaluate the tissue expression of squamous cell carcinoma antigen (SCCA) in oesophageal dysplasia and squamous cell carcinoma (SCC) with reference to its clinico-pathologic and prognostic significance. " 02/01/2007 - "Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma." 10/01/2002 - "The aim of this study was to retrospectively examine whether the occurrence of squamous cell carcinoma (SCC) antigen tumour marker in the serum has prognostic significance in operable SCC of the cervix at the International Federation of Gynaecology and Obstetrics (FIGO) stages IA2-IIB. " 02/01/1998 - "The purpose of this study was to assess the clinical value of CYFRA for squamous cell carcinoma of the head and neck and compare the results with squamous cell carcinoma antigen (SCCA). " Order ALL the reference details at left...
3.	Vulvar Neoplasms (Vulvar Cancer) 06/21/1999 - "In summary, our data indicate that serum concentrations of SCC-Ag may be an additional independent prognostic factor of disease-free and overall survival in patients with vulvar cancer." 09/01/2002 - "STUDY DESIGN: In this retrospective trial, preoperative serum levels of SCC-Ag in 29 patients with invasive squamous cell vulvar cancer (pT1 + 2) were evaluated and compared with nodal status. " 06/01/2005 - "CONCLUSION: SCC-Ag serum levels cannot be used as an additional prognostic parameter in patients with surgically treated early stage vulvar cancer." 06/01/2005 - "RESULTS: Mean (standard deviation) SCC-Ag serum levels in patients with vulvar cancer were 1.5 (1.99) ng/mL. SCC-Ag serum levels were significantly higher in patients with pT2 vulvar cancer (2.2 [2.6] ng/mL) compared with patients with pT1 vulvar cancer (1.0 [1.2] ng/mL, P = 0.034). " 06/01/2005 - "METHODS: SCC-Ag serum levels were measured preoperatively in 61 surgically staged patients with squamous cell vulvar cancer (UICC pT1 and pT2). " Order ALL the reference details at left...
4.	Carcinoma (Carcinomatosis) 12/01/2006 - "Group C patients were in complete remission after previous definitive treatment for histologically confirmed cervical carcinoma but had elevated serum squamous cell carcinoma antigen (tumour marker) levels despite negative CT-MRI. " 01/01/2009 - "This study was to investigate the significance of pretreatment serum CYFRA21-1 and squamous cell carcinoma antigen (SCCAg) in diagnosis and their correlations to the clinicopathologic features of cervical carcinoma. " 01/01/1995 - "Squamous cell carcinoma antigen (SCCA) has shown in different studies to be an effective means of monitoring the course of the disease in cervical carcinoma. " 11/01/1992 - "The results of our study indicated that the determination of SCC antigen would be clinically useful for monitoring clinical courses of patients with uroepithelial carcinomas containing SCC component and of those with pure TCC whose pretreatment level was elevated." 01/01/1992 - "The work presents the results of studies on the behaviour of SCC antigen in 52 patients aged 21-70 years, with pathologic changes involving the uterine cervix and classified to the groups of erosion, dysplasia and carcinoma in different stage of advancement. " Order ALL the reference details at left...
5.	Neoplasm Metastasis (Metastasis) 01/01/2009 - "CONCLUSIONS: SCC-Ag (>1.65 ng/mL) can predict LN metastases more accurately in stage IB1 than in stage IB2+ IIA. " 01/01/2009 - "The accuracy to predict LN metastases of SCC-Ag at ROC established cutoff of 1.65 ng/mL and 5.5 ng/mL was 76% and 78%, respectively, in stage IB1, and 53% and 79%, respectively, in stages IB2+ IIA. " 11/01/2008 - "However, squamous cell carcinoma antigen could not accurately predict occult inguinal lymph node metastasis in clinically node negative cases. " 11/01/2007 - "However, it is of limited value in the primary prediction of occult lymph node metastases because the SCC antigen levels increased significantly only after massive lymph node involvement or metastatic disease has occurred. " 11/01/2007 - "RESULTS: Once lymph node metastases occurred, a trend was found toward increased SCC antigen levels and at the stage of organ metastases, the SCC antigen levels had risen significantly (P <0.01). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	squamous cell carcinoma-related antigen
2.	antigen CYFRA21.1
3.	Biological Tumor Markers (Tumor Markers)
4.	Macrophage Colony-Stimulating Factor
5.	Creatinine
6.	urinary gonadotropin fragment
7.	tetraiodothyroacetic acid (TA(4))
8.	Carcinoembryonic Antigen
9.	Phosphopyruvate Hydratase (Enolase)
10.	Tissue Polypeptide Antigen

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Salvage Therapy
3.	Subcutaneous Injections
4.	Hysterectomy
5.	Esophagectomy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>